Profil
Tim Leaver is the founder of Delphic Diagnostics Ltd., which was founded in 2001.
He held the title of Director from 2009 to 2012.
Mr. Leaver also worked as a Finance Director at Serono Ltd.
Mr. Leaver received his undergraduate degree from the University of Warwick in 1988.
Anciens postes connus de Tim Leaver
Sociétés | Poste | Fin |
---|---|---|
Delphic Diagnostics Ltd.
Delphic Diagnostics Ltd. Medical/Nursing ServicesHealth Services Delphic is a specialist laboratory company with world-leading capabilities in pharmacology and pharmacogenetics. It was the first company in the world to offer an integrated diagnostics and biomarker service in HIV and is now applying that model in hepatitis. It has particular expertise in infectious diseases, including capabilities in study design and in method development and transfer, and a growing clinical trials portfolio. It is planning to apply its expertise to other therapy areas. Delphic is growing, organically and by acquisition, into a specialist biomarker and companion diagnostics company able to support the growing demand for personalised medicine in clinical therapy and in drug development. Its laboratories are certified to ISO, GCLP, CAP and CLIA. It has global reach via its own laboratories in the UK and partner laboratories in Italy, Spain, Greece and Argentina. | Fondateur | 03/10/2012 |
Serono Ltd. | Directeur Financier/CFO | - |
Formation de Tim Leaver
University of Warwick | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Delphic Diagnostics Ltd.
Delphic Diagnostics Ltd. Medical/Nursing ServicesHealth Services Delphic is a specialist laboratory company with world-leading capabilities in pharmacology and pharmacogenetics. It was the first company in the world to offer an integrated diagnostics and biomarker service in HIV and is now applying that model in hepatitis. It has particular expertise in infectious diseases, including capabilities in study design and in method development and transfer, and a growing clinical trials portfolio. It is planning to apply its expertise to other therapy areas. Delphic is growing, organically and by acquisition, into a specialist biomarker and companion diagnostics company able to support the growing demand for personalised medicine in clinical therapy and in drug development. Its laboratories are certified to ISO, GCLP, CAP and CLIA. It has global reach via its own laboratories in the UK and partner laboratories in Italy, Spain, Greece and Argentina. | Health Services |
Serono Ltd. |